1 Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK.
2 Global Health R&D, GlaxoSmithKline, Tres Cantos, Spain.
3 David Jack Centre for R&D, GlaxoSmithKline, Ware, UK.
4 Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.
5 Wellcome Sanger Institute, Cambridge, UK.
6 Centre of Immunobiology, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
7 Cellzome GmbH, A GlaxoSmithKline Company, Heidelberg, Germany.
8 GlaxoSmithKline, New Frontiers Science Park, Harlow, UK.
9 Global Health R&D, GlaxoSmithKline, Stockley Park West, Uxbridge, UK.
10 Global Health R&D, GlaxoSmithKline, Tres Cantos, Spain. tim.j.miles@gsk.com.
11 Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK. k.read@dundee.ac.uk.
12 Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK. i.h.gilbert@dundee.ac.uk.